In This Article:
As of February 2025, U.S. stock markets are riding high, with major indexes nearing record levels following a rally led by chipmakers like Nvidia. In this context, penny stocks—typically smaller or newer companies—remain an intriguing investment area despite the term's dated origins. For those looking to explore beyond the giants of Wall Street, penny stocks can offer unique opportunities for growth at lower price points when backed by strong financials and solid fundamentals.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.8781 | $6.23M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $120.12M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.275 | $10.3M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.99 | $91.9M | ★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) | $1.42 | $47.19M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
BTCS (NasdaqCM:BTCS) | $3.06 | $53.61M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $1.52 | $23.94M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.91 | $83.05M | ★★★★★☆ |
Information Services Group (NasdaqGM:III) | $3.11 | $161.45M | ★★★★☆☆ |
Click here to see the full list of 704 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Compass Therapeutics
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the U.S. focused on developing antibody-based therapeutics for oncology, with a market cap of $429.28 million.
Operations: Compass Therapeutics, Inc. currently does not report any revenue segments.
Market Cap: $429.28M
Compass Therapeutics, Inc. is a pre-revenue biopharmaceutical firm with a market cap of US$429.28 million, focused on oncology therapeutics. Despite being unprofitable and not expected to achieve profitability in the near term, the company is debt-free and has sufficient cash runway for over a year. Recent developments include progress on multiple clinical trials such as Phase 2 studies for tovecimig and CTX-471, indicating active advancement in its pipeline. Leadership changes have brought experienced executives like Barry Shin as CFO, potentially strengthening financial oversight as Compass navigates its growth trajectory amidst high share price volatility.
-
Dive into the specifics of Compass Therapeutics here with our thorough balance sheet health report.
-
Explore Compass Therapeutics' analyst forecasts in our growth report.
Expensify
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Expensify, Inc. offers a cloud-based expense management software platform catering to individuals, corporations, small and midsized businesses, and enterprises globally, with a market cap of approximately $340.73 million.